Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Immedica Pharma AB
Deal Size: Undisclosed Upfront Cash: $2.1 million
Deal Type: Agreement April 29, 2020
Immedica gets an exclusive distribution and marketing right of the anti-tumor drug lurbinectedin for territories that include the UK, Ireland, the Nordic countries, Middle East and North Africa.